Sugi Predict

Sugi Predict / Compounds / SCHEMBL46742

SCHEMBL46742

SCHEMBL46742

Nc1ncc2cc(Br)ccc2n1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BACE1 P56817 2/20 0.55
▸ PABPC1 P11940 1/20 0.53
▸ LCK P06239 2/20 0.49
▸ KDR P35968 1/20 0.49
▸ JAK3 P52333 1/20 0.49
▸ MAPK14 Q16539 1/20 0.49
▸ CLK1 P49759 3/20 0.47
▸ CSNK1D P48730 1/20 0.47
▸ CSNK1E P49674 1/20 0.47
▸ DYRK1A Q13627 1/20 0.47
▸ KDM4E B2RXH2 1/20 0.42
▸ MEN1 O00255 1/20 0.42
▸ ALDH1A1 P00352 1/20 0.42
▸ MAPT P10636 1/20 0.42
▸ KMT2A Q03164 1/20 0.42
▸ HTT P42858 1/20 0.41
▸ ROCK1 Q13464 1/20 0.41
▸ ADORA2A P29274 1/20 0.40
▸ CDK5 Q00535 2/20 0.39
▸ CDK5R1 Q15078 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29699229 1.00 BACE1 (0.55) BACE1PABPC1LCKKDRJAK3
SCHEMBL5132808 0.84 KDR (0.48) BACE1PABPC1LCKKDRJAK3
SCHEMBL1741867 0.84 BACE1 (0.57) BACE1PABPC1KDRCLK1CSNK1D
SCHEMBL30380023 0.84 BACE1 (0.57) BACE1PABPC1KDRCLK1CSNK1D
SCHEMBL1461279 0.79 BACE1 (0.48) BACE1PABPC1DYRK1AKDM4EMEN1
SCHEMBL30839232 0.79 BACE1 (0.48) BACE1PABPC1DYRK1AKDM4EMEN1
SCHEMBL30912753 0.79 EGFR (0.57) LCKKDRJAK3MAPK14CLK1
SCHEMBL610225 0.79 EGFR (0.57) LCKKDRJAK3MAPK14CLK1
SCHEMBL1570979 0.76 BACE1 (0.46) BACE1PABPC1MEN1KMT2AHTT
SCHEMBL15679285 0.76 LCK (0.49) LCKKDRJAK3MAPK14CLK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 141 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-105669566-A Preparation method of pharmaceutical intermediate N-arylquinazolinyl-amine compounds 华东师范大学 2016-06-15 — — CN claimed
US-12630529-B2 GCN2 modulator compounds Alesta Therapeutics BV (NL) 2026-05-19 — — US disclosed
US-12479818-B2 Treatment of fibrosis with IRE1 small molecule inhibitors CORNELL UNIVERSITY (US) 2025-11-25 — — US disclosed
US-20250340530-A1 GCN2 INHIBITOR (as amended) IP2IPO INNOVATIONS LTD (GB) 2025-11-06 — — US disclosed
EP-3707126-B1 IRE1 SMALL MOLECULE INHIBITORS UNIV CORNELL (US) 2025-05-14 — — EP disclosed
EP-4522610-A1 GCN2 INHIBITORR IP2IPO Innovations Limited (GB) 2025-03-19 — — EP disclosed
CN-119451955-A GCN2 inhibitors IP2IPO创新有限公司 2025-02-14 — — CN disclosed
US-20240425477-A1 IRE1 SMALL MOLECULE INHIBITORS CORNELL UNIVERSITY 2024-12-26 — — US disclosed
US-20240376058-A1 GCN2 AND PERK KINASE INHIBITORS AND METHODS OF USE THEREOF DECIPHERA PHARMACEUTICALS, LLC 2024-11-14 — — US disclosed
US-20240294524-A1 HETEROCYCLIC COMPOUNDS USEFUL AS PDK1 INHIBITORS OXFORD FINANCE LLC, AS COLLATERAL AGENT 2024-09-05 — — US disclosed
CN-101056635-A Niacin receptor agonists, compositions containing such compounds and methods of treatment MERCK & CO INC (US) 2007-10-17 — — CN disclosed
EP-1836174-A2 ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS AMGEN INC. (US) 2007-09-26 — — EP disclosed
CN-101039914-A Trifluoromethyl substituted benzamide compounds as kinase inhibitors NOVARTIS AG (CH) 2007-09-19 — — CN disclosed
EP-1778640-A1 TRIFLUOROMETHYL SUBSTITUTED BENZAMIDES AS KINASE INHIBITORS Novartis AG (CH) 2007-05-02 — — EP disclosed
US-20070054916-A1 Aryl nitrogen-containing bicyclic compounds and methods of use AMGEN INC. 2007-03-08 — — US disclosed
US-20070054916-A1 Aryl nitrogen-containing bicyclic compounds and methods of use AMGEN INC. 2007-03-08 — — US disclosed
US-20070054916-A1 Aryl nitrogen-containing bicyclic compounds and methods of use AMGEN INC. 2007-03-08 — — US disclosed
WO-2006039718-A2 ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS AMGEN INC (US) 2006-04-13 — — WO disclosed
WO-2006015859-A1 TRIFLUOROMETHYL SUBSTITUTED BENZAMIDES AS KINASE INHIBITORS NOVARTIS AG (CH) 2006-02-16 — — WO disclosed
US-20060035897-A1 Trifluoromethyl substituted benzamides as kinase inhibitors NOVARTIS AG (CH) 2006-02-16 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12630529-B2 GCN2 modulator compounds NR3C1, GCN1, EIF2AK4 BACE1 4366/4885PABPC1 2779/4885LCK 4660/4885
US-20250340530-A1 GCN2 INHIBITOR (as amended) EIF2AK4, GCN1, GCGR BACE1 4350/4885PABPC1 645/4885LCK 4310/4885
US-20240425477-A1 IRE1 SMALL MOLECULE INHIBITORS XBP1, ERN2, ERN1 BACE1 2851/4885PABPC1 215/4885LCK 2304/4885
US-20240294524-A1 HETEROCYCLIC COMPOUNDS USEFUL AS PDK1 INHIBITORS PDK1, PDK2, PDK3 BACE1 3904/4885PABPC1 1429/4885LCK 554/4885
US-20240376058-A1 GCN2 AND PERK KINASE INHIBITORS AND METHODS OF USE THEREOF EIF2AK4, GCN1, EEF2K BACE1 3897/4885PABPC1 541/4885LCK 1565/4885
US-12479818-B2 Treatment of fibrosis with IRE1 small molecule inhibitors XBP1, DDIT3, HSP90B1 BACE1 2728/4885PABPC1 456/4885LCK 3558/4885
US-20060035897-A1 Trifluoromethyl substituted benzamides as kinase inhibitors ABL1, ERBB2, EPHB2 BACE1 2162/4885PABPC1 3132/4885LCK 59/4885
US-20070054916-A1 Aryl nitrogen-containing bicyclic compounds and methods of use MAP3K1, MAP3K5, MAP3K2 BACE1 3036/4885PABPC1 2591/4885LCK 106/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.